Delving into the Latest Updates on Autologous gamma delta T cell therapy (TC BioPharm) with Synapse

Overview

Basic Info

Drug Type

T-lymphocyte cell therapy

Synonyms

Autologous T Lymphocytes, Autologous d T Lymphocytes, Autologous g T Lymphocytes

+ [1]

Target-

Mechanism

Immunologic cytotoxicity, T lymphocyte replacements

Therapeutic Areas

NeoplasmsRespiratory DiseasesSkin and Musculoskeletal Diseases+ [2]

Active Indication-

Inactive Indication

Kidney NeoplasmsLiver CancerMelanoma+ [1]

Originator Organization

TC Biopharm Ltd.

Active Organization-

Inactive Organization

TC Biopharm Ltd.M Group Holdings Ltd.

Drug Highest PhaseDiscontinuedPhase 2/3

First Approval Date-

Regulation-

Login to view timeline

Safety and Efficacy of Ex-vivo Expanded Allogeneic γδ T-lymphocytes (OmnImmune®) in Patients With Active Relapsed or Refractory Acute Myeloid Leukaemia (AML) Who Are Not Eligible for or do Not Consent to High Dose Salvage Chemotherapy and/or Allogeneic Haematopoietic Cell Transplantation (HCT). A Dose Escalation, Open-label, Phase I Study

This study investigates the potential curative properties of gamma delta T-cells obtained from a blood-related donor of an AML patient.

Start Date27 Nov 2018

Sponsor / Collaborator

TC Biopharm Ltd.

NCT02459067 / TerminatedPhase 2

Adaptive Study of the Safety, Tolerability & Efficacy of Autologous γδ T Lymphocyte Therapy (ImmuniCell®) in Patients With Advanced Cancers Refractory to Current Treatment or Have Indolent Disease for Which Immunotherapy May be Beneficial

To determine the safety, tolerability, maximum tolerated dose (MTD) and efficacy of ImmuniCell® in patients with melanoma, renal cell cancer (RCC) or non-small cell lung cancer (NSCLC). The study is an adaptive design that has 3 stages: Stage 1 - dose escalation, Stage 2 - efficacy, and Stage 3 - confirm efficacy in one of the tumor types.

Start Date01 Dec 2015

Sponsor / Collaborator

TC Biopharm Ltd.

JPRN-UMIN000006128 / CompletedPhase 2IIT

Adoptive immunotherapy using zoledronate-expanded autologous gamma/delta T cells for patients with non-small cell lung cancer refractory to standard treatment. - Zoledronate-expanded autologous gamma/delta T cell therapy for NSCLC

Start Date01 Jul 2012

Sponsor / Collaborator

The University of Tokyo Hospital

100 Clinical Results associated with Autologous gamma delta T cell therapy (TC BioPharm)

Login to view more data

100 Translational Medicine associated with Autologous gamma delta T cell therapy (TC BioPharm)

Login to view more data

100 Patents (Medical) associated with Autologous gamma delta T cell therapy (TC BioPharm)

Login to view more data

3

Literatures (Medical) associated with Autologous gamma delta T cell therapy (TC BioPharm)

25 Oct 2024·Organic Letters

Cinchona Organocatalyzed Enantioselective Amination for Quaternized Serines as Tertiary Amides

Article

Author: Spicer, Christopher D. ; Hunter, Roger ; Bhana, Ashlyn D. ; Venter, Gerhard A. ; Su, Hong ; Petersen, Wade F. ; Masithi, Phathutshedzo

Herein, we describe a Cinchona-aminocatalyzed enantioselective α-hydrazination of an α-formyl amide for the production of protected quaternized serines as tertiary amides with ee's of generally >98% and ≤99% yields. The proposed TS model supported by density functional theory calculations involves a quinuclidinium ion Brønsted acid-assisted delivery of D^tBAD, which occurs from the Re face of an H-bonded enaminone when using a 9S-cinchonamine catalyst, resulting in a hydrazide with the R-configuration as determined by X-ray analysis.

01 Sep 2011·British Journal of CancerQ1 · MEDICINE

Clinical evaluation of autologous gamma delta T cell-based immunotherapy for metastatic solid tumours

Q1 · MEDICINE

Article

Author: S R Mattarollo ; T Hagi ; H Tokuyama ; K Yokokawa ; K Suzuki ; M Nieda ; A J Nicol

BACKGROUNDAdoptive transfer of ex vivo expanded autologous Vγ9Vδ2 T cells may be of therapeutic benefit for cancer because of their potent direct cytotoxicity towards tumour cells, synergistic cytotoxicity when combined with aminobisphosphonates and enhancement of antibody-dependent cell-mediated cytotoxicity.METHODSTo determine the feasibility and clinical safety of therapy with ex vivo expanded, activated Vγ9Vδ2 T cells in combination with zoledronate, we enrolled 18 subjects with advanced solid tumours into a phase I clinical study. Administered indium(111)-oxine-labelled Vγ9Vδ2 T cells were tracked in a cohort of patients.RESULTSAdministered Vγ9Vδ2 T cells had an activated effector memory phenotype, expressed chemokine receptors predictive of homing to peripheral tissues and were cytotoxic in vitro against tumour targets. Adoptively transferred Vγ9Vδ2 T cells trafficked predominantly to the lungs, liver and spleen and, in some patients, to metastatic tumour sites outside these organs. No dose-limiting toxicity was observed, but most patients progressed on study therapy. However, three patients administered Vγ9Vδ2 T cells while continuing previously ineffective therapy had disease responses, suggesting an additive effect.CONCLUSIONTherapy with aminobisphosphonate-activated Vγ9Vδ2 T cells is feasible and well tolerated, but therapeutic benefits appear only likely when used in combination with other therapies.

01 Mar 2007·The Journal of Physical Chemistry AQ3 · CHEMISTRY

Geometric Structure of X(AuPH₃)₄⁺ (X = N, P, As, Sb): T_d or C₄_v?

Q3 · CHEMISTRY

Article

Author: Fang, Hua ; Wang, Shu-Guang

The geometric structures of X(AuPH3)4+ (X = N, P, As, Sb) compounds have been determined by DFT and ab-initio methods. In agreement with experiment, N(AuPH3)4+ is Td and As(AuPH3)4+ is C4v with an apical As atom. Calculated molecular and experimental crystal structure parameters are compared. The structures of X(AuPH3)4+ (X = P, Sb) are predicted. P(AuPH3)4+ favors Td, as confirmed by CC2. The closed-shell interaction distances of Au...Au from Xalpha are consistent with the experimental values. The electronic structures and chemical deformation densities are analyzed.

100 Deals associated with Autologous gamma delta T cell therapy (TC BioPharm)

Login to view more data

R&D Status

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Kidney Neoplasms	Phase 3	GB	TC Biopharm Ltd.	-
Liver Cancer	Phase 3	JP	M Group Holdings Ltd.	-
Melanoma	Phase 3	GB	TC Biopharm Ltd.	-
Non-Small Cell Lung Cancer	Phase 3	GB	TC Biopharm Ltd.	-

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


ASCO2011	Not Applicable	Early Stage Breast Carcinoma Adjuvant	74	TC therapy	xcskpilzdn(tljpmznezn) = kzxlojbeex bxevcbztey (mydiybrrmv )	-	20 May 2011
				docetaxel (No prophylaxis)	xcskpilzdn(tljpmznezn) = rsptoqbbko bxevcbztey (mydiybrrmv )
Tandem Meetings ASTCT and CIBMTR2009	Not Applicable	Lymphoma	-	Autologous Cytotoxic T Lymphocytes (LMP2 CTLs)	dsztcrcdcj(pauhetiiby) = zdfoqqntmr iclhgalmiw (uagdevqyev ) View more	-	01 Feb 2009
				Autologous Cytotoxic T Lymphocytes (LMP1/2 CTLs)	rvyivqkqln(ggwyxbdtns) = cchfujqcby tbhddrgnqp (dacrshhwsg )